Albumedix has announced the formation of a Scientific Advisory Board (SAB) to provide governance, oversight and advice to Albumedix’s R&D organisation as it builds and develops its pipeline of proprietary and differentiated drugs.
The SAB, chaired by Dr John Westwick, includes distinguished individuals with deep relevant experience in science and pharmaceutical medicine.
It will form a key strategic resource for the company, bringing unique perspectives and additional expertise to guide internal drug development programmes.
Dr Westwick will be joined by Dr Gary Patou, executive partner, MPM Capital and Chief Medical Officer for various portfolio companies; Dr Jennifer Sims, Founder and Managing Director, Integrated Biologiix; and Professor Inger Sandlie of the University of Oslo.
Dr Giles Campion, Chief Medical Officer at Albumedix, said: “The establishment of the SAB is part of Albumedix’s on-going strategy of advancing our albumin-based drug delivery platform to support the development of improved biotherapeutics.
“Pipeline building and development requires a combination of rigorous science, efficient processes, sound strategic choices and commercial acumen. The members of the SAB encompass all these needs in abundance and I look forward to receiving their advice and input as we build a sustainable and valued portfolio of drug candidates based on our expertise in albumin.”
Dr John Westwick, Chairman SAB at Akbumedix: “I am delighted to have been asked to chair Albumedix’s SAB. The diverse expertise of the group will provide Albumedix with broad scientific perspectives, guiding the company in its development efforts to advance albumin-based therapies to the clinic.”
